Evidence map›Paper›PMID 31506552›Full record

ArticleScientific reports2019

The double inhibition of PDK1 and STAT3-Y705 prevents liver metastasis in colorectal cancer.

Wenjuan Qin, Yun Tian, Jing Zhang, Wenjian Liu, Qiming Zhou, Sheng Hu, Fei Yang, Li Lu, Haijie Lu, Shuzhong Cui and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Wenjuan QinDepartment of Radiation Oncology, Zhongshan Hospital Affiliated by Xiamen University, Xiamen, Fujian, China.
Yun TianDepartment of Abdominal Surgery, The Cancer Hospital Affiliated by Guangzhou Medical University, Guangzhou, Guangdong, China.
Jing ZhangDepartment of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Wenjian LiuDepartment of Hematological Oncology, Sun Yat-Sen Cancer Center, Guangzhou, Guangdong, China.
Qiming ZhouDepartment of Oncology, The Sixth People's Hospital, Shenzhen, Guangdong, China.
Sheng HuDepartment of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Fei YangDepartment of Pathology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Li LuDepartment of Gastrointestinal Surgery & Colorectal Cancer Center of Hubei Province, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Haijie LuDepartment of Radiation Oncology, Zhongshan Hospital Affiliated by Xiamen University, Xiamen, Fujian, China.
Shuzhong CuiDepartment of Abdominal Surgery, The Cancer Hospital Affiliated by Guangzhou Medical University, Guangzhou, Guangdong, China.
Lu WenCancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. wenlu2808@126.com.
Shaozhong WeiDepartment of Gastrointestinal Surgery & Colorectal Cancer Center of Hubei Province, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. weishaozhong1@163.com.
Huazhong University of Science and Technology · CNGuangzhou Medical University · CNZhongshan Hospital of Xiamen University · CNHubei Cancer Hospital · CNShenzhen Sixth People's Hospital · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a key glycolysis enzyme, the significance of pyruvate dehydrogenase kinase 1 (PDK1) in the development of colorectal cancer (CRC) remains unknown. This study revealed that the prognosis of CRC patients with high levels of PDK1 was poor, and PDK1 knockdown significantly reduced liver metastasis of CRC in both nude mice and immune competent BALB/C mice. When combined with cryptotanshinone (CPT), an inhibitor of STAT3-p-Y705, the liver metastasis was further inhibited. PDK1 knockdown obviously increased reactive oxygen species level in anoikis conditions and subsequently resulted in an elevated anoikis, but the combination of PDK1 knockdown and CPT showed a reduced effect on anoikis. Based on this discrepancy, the adherence ability of CRC cells to matrix protein fibronectin was further detected. It showed that PDK1 knockdown significantly decreased the adherence of CRC cells to fibronectin when combined with CPT. These results suggest that inhibition of PDK1 can decrease the surviving CRC cells in blood circulation via up-regulation of anoikis, and inhibition of STAT3-p-Y705 can prevent it to settle down on the liver premetastatic niche, which ultimately reduces liver metastasis.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsApoptosisBiomarkers, TumorCell MovementCell ProliferationColorectal NeoplasmsFemaleHumansLiver NeoplasmsMaleMiceMice, Inbred BALB CMice, NudePhenanthrenesPhosphorylationBiomarkers, TumorcryptotanshinonePDK1 protein, humanPhenanthrenesPyruvate Dehydrogenase Acetyl-Transferring KinaseSTAT3 protein, humanSTAT3 Transcription Factor

Identifiers

PMID31506552
PMCPMC6736869
OpenAlexW2972861119

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.